

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of <b>E. Kostenis et al.</b>	Examiner: <b>S. Priebe</b> Art Unit: <b>1633</b>
---	---

Application No.: **10/706,763**

Filed: **November 12, 2003**

Title: **Use of EDG2 Receptor in An Animal  
Model of Heart Failure**

### RESPONSE TO OFFICE COMMUNICATION

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Communication dated February 17, 2006 in the above-referenced application, Applicants respectfully amend the specification to claim subject matter disclosed in prior application NO. PCT/EP03/12325. Applicants cancel Claims 6-8, withdraw Claims 11-24, and amend the claims 1 & 9 with "non-human mammals" for allowance. Applicants reserve the right to file one or more divisional applications directed to the non-elected subject matter in this application.

A request for a five-month extension of time and the required fee accompany this amendment, extending the period of reply to July 17, 2006. The Commissioner is authorized to charge the extension fee or any additional fees or credit any overpayment necessitated by this response to Deposit Account No. 18-1982.

Please amend the **specification** as set forth on page 2 of this paper

Please amend the **claims** as set forth on page 3 of this paper.

Please consider the **remarks** as set forth on page 5 of this paper.